LILIANA BUSTAMANTE MD NPI 1881987303

NPI Details

Liliana Bustamante, MD is a medical oncology internal medicine in Cape Coral, FL with 15 years of experience. The provider is an internist who specializes in the diagnosis and treatment of all types of cancer and other benign and malignant tumors. This specialist decides on and administers therapy for these malignancies as well as consults with surgeons and radiotherapists on other treatments for cancer. Liliana Bustamante, MD NPI is 1881987303. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
Graduation Year:2011

The provider's business location address is:

1030 COMMERCE CREEK BLVD
CAPE CORAL, FL
ZIP 33909-529
Phone: (239) 772-3544
Fax: (239) 772-7855

The NPI 1881987303 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Transferrin (iron binding protein) level (HCPCS:84466)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Measurement of immunoglobulin light chains (HCPCS:83521)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Folic acid level, serum (HCPCS:82746)
• Magnesium level (HCPCS:83735)
• Protein measurement, serum (HCPCS:84165)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection of drug or substance into vein (HCPCS:96374)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Automated urinalysis test (HCPCS:81003)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Iron binding capacity (HCPCS:83550)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Phosphate level (HCPCS:84100)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection, methylprednisolone sodium succinate, up to 40 mg (HCPCS:J2920)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Uric acid level, blood (HCPCS:84550)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Red blood count, manual test (HCPCS:85044)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Telephone medical discussion with physician, 11-20 minutes (HCPCS:99442)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)

The enumeration date for this NPI number is 5/17/2011 and was last updated on 8/2/2022.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.